Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat - PubMed (original) (raw)
. 1999 Jan 15;52(2):273-9.
doi: 10.1212/wnl.52.2.273.
Affiliations
- PMID: 9932943
- DOI: 10.1212/wnl.52.2.273
Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat
R L Zhang et al. Neurology. 1999.
Abstract
Objective: To examine the efficacy of an antileukocyte adhesion antibody (anti-CD18) as an adjuvant for delayed (2 hours and 4 hours) thrombolytic therapy (recombinant human tissue plasminogen activator [rt-PA]) in middle cerebral artery occlusion (MCAO) in rats.
Background: Thrombolytic therapy with rt-PA is limited in its application by a short therapeutic window.
Methods: Male Wistar rats were subjected to MCAO by a single fibrin-rich clot. The rats were assigned to the following experimental groups: Experiment 1 (treatment 2 hours after embolization), 1) rt-PA, 2) anti-CD18 antibody, 3) rt-PA and anti-CD18 antibody, 4) immunoglobulin (Ig) G, and 5) vehicle; Experiment 2 (treatment 4 hours after occlusion), 1) rt-PA alone, 2) rt-PA and anti-CD18 antibody, and 3) nontreated control group. Neurologic deficits, infarction volume, hemorrhage, and brain myeloperoxidase (MPO) immunoreactivity were measured.
Results: Administration of rt-PA and anti-CD18 antibody 2 hours later reduced significantly (p < 0.05) the infarct volume and improved neurologic deficits compared with the vehicle-treated group. Treatment with rt-PA alone improved neurologic deficits significantly and reduced mean infarct volume compared with the vehicle-treated group. However, treatment with anti-CD18 antibody neither reduced infarct volume nor improved neurologic deficits compared with the IgG-treated group. The combination of rt-PA and anti-CD18 antibody treatment at 4 hours reduced significantly the infarct volume and MPO immunoreactive cells compared with rt-PA treatment alone at 4 hours, and reduced neurologic deficits compared with rt-PA treatment alone and compared with the nontreated animals.
Conclusions: The combination of antileukocyte adhesion antibody and thrombolytic therapy may increase the therapeutic window for the treatment of stroke.
Similar articles
- Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Zhang L, et al. Stroke. 2003 Jul;34(7):1790-5. doi: 10.1161/01.STR.0000077016.55891.2E. Epub 2003 Jun 12. Stroke. 2003. PMID: 12805500 - Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
Jiang Q, Zhang RL, Zhang ZG, Ewing JR, Divine GW, Chopp M. Jiang Q, et al. J Cereb Blood Flow Metab. 1998 Jul;18(7):758-67. doi: 10.1097/00004647-199807000-00007. J Cereb Blood Flow Metab. 1998. PMID: 9663506 - Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.
Zhang RL, Zhang ZG, Chopp M, Zivin JA. Zhang RL, et al. Stroke. 1999 Mar;30(3):624-9. doi: 10.1161/01.str.30.3.624. Stroke. 1999. PMID: 10066862 - Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke.
Overgaard K, Sereghy T, Pedersen H, Boysen G. Overgaard K, et al. Neurol Res. 1993 Oct;15(5):344-9. doi: 10.1080/01616412.1993.11740159. Neurol Res. 1993. PMID: 7905610 - New developments in thrombolytic therapy.
Collen D, Gold HK. Collen D, et al. Adv Exp Med Biol. 1990;281:333-54. Adv Exp Med Biol. 1990. PMID: 2129372 Review.
Cited by
- Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke.
Hemmen TM, Lyden PD. Hemmen TM, et al. Stroke. 2009 Mar;40(3 Suppl):S126-8. doi: 10.1161/STROKEAHA.108.533083. Epub 2008 Dec 8. Stroke. 2009. PMID: 19064802 Free PMC article. - Inflammation in adult and neonatal stroke.
Vexler ZS, Tang XN, Yenari MA. Vexler ZS, et al. Clin Neurosci Res. 2006 Dec 1;6(5):293-313. doi: 10.1016/j.cnr.2006.09.008. Clin Neurosci Res. 2006. PMID: 20300490 Free PMC article. - The Inflammatory Response After Ischemic Stroke: Targeting β2 and β1 Integrins.
Edwards DN, Bix GJ. Edwards DN, et al. Front Neurosci. 2019 May 28;13:540. doi: 10.3389/fnins.2019.00540. eCollection 2019. Front Neurosci. 2019. PMID: 31191232 Free PMC article. Review. - A review of current imaging methods used in stroke research.
Wey HY, Desai VR, Duong TQ. Wey HY, et al. Neurol Res. 2013 Dec;35(10):1092-102. doi: 10.1179/1743132813Y.0000000250. Epub 2013 Aug 16. Neurol Res. 2013. PMID: 24070268 Free PMC article. Review. - Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke.
Zhang RL, Zhang C, Zhang L, Roberts C, Lu M, Kapke A, Cui Y, Ninomiya M, Nagafuji T, Albala B, Zhang ZG, Chopp M. Zhang RL, et al. Stroke. 2008 Oct;39(10):2830-6. doi: 10.1161/STROKEAHA.108.515684. Epub 2008 Jul 31. Stroke. 2008. PMID: 18669895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous